Recent publications by Researchers affiliated with the Centre for Tropical Medicine and Global Health
Triple artemisinin-based combination therapies for malaria: proceed with caution - Authors' reply.
van der Pluijm RW. et al, (2021), Lancet (London, England), 396, 1976 - 1977
Evolution of Multidrug Resistance in Plasmodium falciparum: a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion
Imwong M. et al, (2021), Antimicrobial Agents and Chemotherapy, 65
Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
Hamaluba M. et al, (2021), The Lancet. Infectious diseases, 21, 1395 - 1406
Letter to the editor RE: Reuling et al., 2018 'liver injury in uncomplicated malaria is an overlooked phenomenon: An observational study'.
Dondorp AM. et al, (2021), EBioMedicine, 68
Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations.
Tindana P. et al, (2021), Malaria journal, 20
Triple Artemisinin-Based Combination Therapies for Malaria - A New Paradigm?
van der Pluijm RW. et al, (2021), Trends in parasitology, 37, 15 - 24
Modulation of Triple Artemisinin-Based Combination Therapy Pharmacodynamics by Plasmodium falciparum Genotype.
Ansbro MR. et al, (2020), ACS pharmacology & translational science, 3, 1144 - 1157
Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study
Imwong M. et al, (2020), The Lancet Infectious Diseases, 20, 1470 - 1480
A comprehensive RNA handling and transcriptomics guide for high-throughput processing of Plasmodium blood-stage samples.
Kucharski M. et al, (2020), Malaria journal, 19
Safety, Pharmacokinetics, and Mosquito-Lethal Effects of Ivermectin in Combination With Dihydroartemisinin-Piperaquine and Primaquine in Healthy Adult Thai Subjects.
Kobylinski KC. et al, (2020), Clinical pharmacology and therapeutics, 107, 1221 - 1230
Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial (vol 395, pg 1345, 2020)
van der Pluijm RW. et al, (2020), LANCET, 395, 1344 - 1344
Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial
van der Pluijm RW. et al, (2020), The Lancet, 395, 1345 - 1360
Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study
van der Pluijm RW. et al, (2019), The Lancet Infectious Diseases, 19, 952 - 961
Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study
Hamilton WL. et al, (2019), The Lancet Infectious Diseases, 19, 943 - 951
Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperaquine and Mefloquine in Healthy Thai Adults.
Hanboonkunupakarn B. et al, (2019), Antimicrobial agents and chemotherapy, 63
The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial
von Seidlein L. et al, (2019), PLOS Medicine, 16, e1002745 - e1002745
EVOLUTION AND EXPANSION OF MULTI-DRUG RESISTANT MALARIA IN SOUTHEAST ASIA
Hamilton WL. et al, (2019), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 101, 500 - 500
The origins of malaria artemisinin resistance defined by a genetic and transcriptomic background
Zhu L. et al, (2018), Nature Communications, 9
Investigating the Efficacy of Triple Artemisinin-Based Combination Therapies for Treating Plasmodium falciparum Malaria Patients Using Mathematical Modeling
Dini S. et al, (2018), Antimicrobial Agents and Chemotherapy, 62
Antimalarial Resistance Unlikely To Explain U.K. Artemether-Lumefantrine Failures
van der Pluijm RW. et al, (2017), Antimicrobial Agents and Chemotherapy, 61